title: UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.
abstract: Mutations in theUGT1A1gene have been implicated in Gilbert syndrome, which shows mild hyperbilirubinemia, and a more aggressive childhood subtype, Crigler-Najjar syndrome. To date, more than 100 variants have been found in theUGT1A1gene. Among them,UGT1A1*28andUGT1A1*6have been reported to be associated with severe toxicities in patients treated with irinotecan-based chemotherapy by increasing the dose of SN-38 (7-ethyl-10-hydroxycamptothecin), an active form of irinotecan. Many association studies and meta-analyses have demonstrated the contribution ofUGT1A1*28andUGT1A1*6polymorphisms to the toxicities caused by irinotecan-based therapy. The aim of this review was to evaluate the impact of these variants upon the toxicities and the efficacy of irinotecan-based chemotherapy.
authors.affiliation: Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama.
authors.forename: Masashi
authors.initials: M
authors.lastname: Takano
authors.affiliation: Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
keywords: UGT1A1; chemotherapy; irinotecan; response; survival; toxicity